{
  "id": 8227311,
  "title": "Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition",
  "url": "https://urgent.news/2026/09/18/vulnerability-of-triple-negative-breast-cancer-to-daraxonrasib-pan",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-18T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.16.752096v1?rss=1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Triple-Negative Breast Cancer (TNBC) is a clinical subtype where aberrant expression of receptor tyrosine kinases (RTKs) leads to the activation of the RAS-RAF-MEK-ERK pathway contributing to tumor progression. Therapies targeting components of the RAF-MEK-ERK pathway in TNBC have been disappointing due to rapid onset of adaptive reprogramming of the RTK landscape leading to pathway reactivation.…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}